written on 10.04.2014
Tags:
,

Hospira wins Herceptin patent suit in U.K., paving way for biosim

TAGS: ,

Hospira is one step closer to selling a Herceptin biosimilar in Britain. The U.S.-based drugmaker persuaded a U.K. court to overturn two Roche patents on the drug. And that means, as of now, Herceptin (trastuzumab) could be open to biosim competition when its main patent expires July 28.

Latest Report